Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E.

Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966. Epub 2019 Jan 24.

2.

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.

Congras A, Caillet N, Torossian N, Quelen C, Daugrois C, Brousset P, Lamant L, Meggetto F, Hoareau-Aveilla C.

Oncotarget. 2018 Feb 8;9(18):14539-14551. doi: 10.18632/oncotarget.24465. eCollection 2018 Mar 6.

3.

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F.

J Clin Invest. 2015 Sep;125(9):3505-18. doi: 10.1172/JCI78488. Epub 2015 Aug 10.

4.

Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.

Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A.

J Immunol. 2013 Oct 1;191(7):3634-40. doi: 10.4049/jimmunol.1300187. Epub 2013 Aug 30.

Supplemental Content

Loading ...
Support Center